Genetic and environmental prediction of opioid cessation using machine learning, GWAS, and a mouse model

Autor: Cox, Jiayi Wu

The United States is currently experiencing an epidemic of opioid use, use disorder, and overdose-related deaths. While studies have identified several loci that are associated with opioid use disorder (OUD) risk, the genetic basis for the ability to

Externí odkaz: https://hdl.handle.net/2144/39401

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An efficient analytic approach in genome-wide identification of methylation quantitative trait loci response to fenofibrate treatment.

Autor: Cox, Jiayi Wu^1,2 jiayiwu@bu.edu, Patel, Devanshi^2,3 dpat@bu.edu, Chung, Jaeyoon^2,3 jychung@bu.edu, Zhu, Congcong² zhucc@bu.edu, Lent, Samantha⁴ lent@bu.edu, Fisher, Virginia⁴ vafisher@bu.edu, Pitsillides, Achilleas⁴ anp4r@bu.edu, Farrer, Lindsay^2,4 farrer@bu.edu, Zhang, Xiaoling^2,4 zhangxl@bu.edu

Publikováno v: BMC Proceedings. 9/17/2018 Supplement 9, Vol. 12 Issue 9, pN.PAG-N.PAG. 1p. 1 Chart, 4 Graphs.

Atp1a2 and Kcnj9 are candidate genes underlying sensitivity to oxycodone-induced locomotor activation and withdrawal-induced anxiety-like behaviors in C57BL/6 substrains.

Autor: Goldberg LR; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.; Graduate Program in Biomolecular Pharmacology, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA USA., Baskin BM; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.; T32 Training Program on Development of Medications for Substance Use Disorder, Center for Drug Discovery, Northeastern University., Adla Y; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Beierle JA; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.; Graduate Program in Biomolecular Pharmacology, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA USA.; Transformative Training Program in Addiction Science, Boston University., Kelliher JC; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Yao EJ; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Kirkpatrick SL; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Reed ER; Graduate Program in Bioinformatics, Boston University, Boston, MA USA., Jenkins DF; Graduate Program in Bioinformatics, Boston University, Boston, MA USA., Cox J; Genetics and Graduate Program in Genetics and Genomics, Program in Biomedical Sciences, Boston University Chobanian & Avedisian School of Medicine., Luong AM; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Luttik KP; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Scotellaro JA; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.; Undergraduate Research Opportunity Program (UROP), Boston University., Drescher TA; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Crotts SB; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA., Yazdani N; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.; Graduate Program in Biomolecular Pharmacology, Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA USA.; Transformative Training Program in Addiction Science, Boston University., Ferris MT; Department of Genetics, University of North Carolina, Chapel Hill, NC USA., Johnson WE; Division of Infectious Disease, Department of Medicine, Center for Data Science, Rutgers University, New Jersey, USA., Mulligan MK; Department of Genetics, Genomics, and Informatics, University of Tennessee Health Science Center, Memphis, TN USA., Bryant CD; Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.; T32 Training Program on Development of Medications for Substance Use Disorder, Center for Drug Discovery, Northeastern University.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Sep 09. Date of Electronic Publication: 2024 Sep 09.